The directors present their annual report and financial statements for the period ended 30 June 2025.
The principle activities of the company continued to be focussed in the area of digital health
The directors who held office during the period and up to the date of signature of the financial statements were as follows:
The first half of 2025 has proven to be a pivotal period, in terms of progression in line with our strategic vision.
In this shortened period to 30 June 2025, we have continued to build upon the operational efficiencies achieved over the previous two years, creating a stronger platform and freeing resources to support our ongoing research and development programme. We continue to make significant investments in R&D, strengthening our position at the forefront of innovation in the digital healthcare market.
Our commitment to R&D ensures that we remain at the cutting-edge, with solutions that meet the evolving needs of people and healthcare systems, both in the UK and internationally. Our R&D programme is focused on creating next-generation digital health technologies. This strategic focus on innovation not only delivers scalability and consistency in outcomes, but also greatly enhances our service offerings, solidifying our reputation as a leader in the digital health industry.
As we add to and build upon partnerships developed with NHS organisations in 2024, we are seeing the positive impact of these continued collaborations with the NHS and the recognition of our ability and commitment to deliver high-quality healthcare solutions not only for the NHS, but also for individuals and organisations on a global scale.
Our Position
At Born Digital Health, we're helping to shape the future of digital health. We believe that no one should suffer from treatable health conditions, and that digital health is one of the best ways to provide fast, effective, reliable, and accessible care.
Throughout this period, we’ve maintained and expanded upon innovative programmes that deliver our unique, personalised support to individuals from socio-economically deprived backgrounds. By focusing on those who would otherwise lack the means to access such support, we proudly demonstrate our strong social conscience and commitment to inclusivity and social impact.
Continued Progress
Our sustained focus on spread, adoption, and integration has resulted in a more scalable and robust service, thanks to ongoing operational improvements and development of strategic partnerships with other leading global organisations.
Continued investment in our people, products, processes, and partnerships has seen us make strides across our priority channels, both in the UK and internationally.
As a digital health service with an international footprint, we support users in multiple countries, delivering excellent outcomes across a wide and varied range of user groups. The exceptional feedback we receive from our service users is a testament to the positive impact we have on their lives every day. Recognising the profound effect of our work, we are committed to further extending our reach to maximise the life-changing impact of our services.
Our People
It is with great pride that we recognise the strong, inclusive, and positive culture within our organisation. Our people are our greatest asset, we know that, and they know that. We thank them for their continued efforts and outstanding contribution.
Our Projections
Increased brand recognition along with a wide and varied service footprint sees us well-positioned for growth and continued positive progression towards our strategic vision, which is to take our uniquely effective means of supporting those with treatable health conditions to a rapidly increasing number of users.
Born Digital Health – Positively impacting lives globally, consistently, effectively.
Born Digital Health Ltd is a private company limited by shares incorporated in England and Wales. The registered office is The Schoolhouse, 12 Trinity Chare, Quayside, Newcastle Upon Tyne, NE1 3DF.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
The average monthly number of persons (including directors) employed by the company during the period was:
Please refer to the Director's report for up to date information on Our People.